Transplant International最新文献

Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-21 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13790

Carlos Jiménez-Romero, Iago Justo Alonso, Oscar Caso Maestro, Alejandro Manrique Municio, Álvaro García-Sesma, Jorge Calvo Pulido, Félix Cambra Molero, Carmelo Loinaz Segurola, Cristina Martín-Arriscado, Anisa Nutu, Alberto Marcacuzco Quinto

{"title":"Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation.","authors":"Carlos Jiménez-Romero, Iago Justo Alonso, Oscar Caso Maestro, Alejandro Manrique Municio, Álvaro García-Sesma, Jorge Calvo Pulido, Félix Cambra Molero, Carmelo Loinaz Segurola, Cristina Martín-Arriscado, Anisa Nutu, Alberto Marcacuzco Quinto","doi":"10.3389/ti.2025.13790","DOIUrl":"10.3389/ti.2025.13790","url":null,"abstract":"Switching the use of calcineurin inhibitors (CNIs), as basal immunosuppression in liver transplantation (LT) patients, for that of mycophenolate mofetil monotherapy (MMF-MT) is currently considered a good measure in recipients with chronic kidney disease (CKD) and other CNI-related adverse effects. We analyzed a retrospective cohort series of 324 LT patients who underwent long-term follow-up and were switched from CNI immunosuppression to MMF-MT due to CKD and other CNI-related adverse effects (diabetes, hypertension, infection). The median time on MMF-MT was 78 months. The indication for MMF-MT was CKD alone or associated with CNI-related adverse effects in 215 patients, diabetes in 61, hypertension in 42, and recurrent cholangitis in 6. Twenty-four (7.4%) patients developed non-resistant acute rejection post-MMF-MT, and 48 (14.8%) patients experienced MMF-related adverse effects, with MMF-MT withdrawn in only 8 (2.5%) patients. In the comparison between the pre-MMF-MT period and the last outpatient review, using a repeated measures model and taking each patient as its own comparator, we demonstrated a significant increase in GFR and significant decrease in creatinine and ALT values, remaining the other variables (diabetes, hypertension, and hematological and AST) within similar levels. Five-year survival post-MMF-MT conversion was 75.3%. MMF-MT significantly improved renal function, was well tolerated, and had a low rejection rate.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"13790"},"PeriodicalIF":2.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomic Analysis of Transbronchial Biopsy Tissue Reveals a Distinct Proteome and Mechanistic Pathways in High-Grade Eosinophilic Inflammation After Lung Transplantation.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.14080

Eisa Tahmasbpour, Ashleigh Philp, Tabitha Cree, Vanathi Sivasubramaniam, Claire Thomson, Marshall Plit, Anjaneyaswamy Ravipati, Mark Raftery, David R Darley

引用次数: 0

Transplant Trial Watch.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-18 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.14375

Simon R Knight, John Fallon

引用次数: 0

Progress in Porcine Kidney Transplantation to Non-Human Primates.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-14 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.14003

Stéphanie Le Bas-Bernardet, Gilles Blancho

{"title":"Progress in Porcine Kidney Transplantation to Non-Human Primates.","authors":"Stéphanie Le Bas-Bernardet, Gilles Blancho","doi":"10.3389/ti.2025.14003","DOIUrl":"https://doi.org/10.3389/ti.2025.14003","url":null,"abstract":"Renal xenotransplantation has recently made considerable progress in overcoming the barrier to its use in humans. This progress has been made possible owing to the use of preclinical pig-to-primate models. Overall, renal xenotransplantation has long been associated with lower survival rates than that of porcine hearts (mainly due to its life-sustaining nature). However, the use of the latest strains of genetically modified porcine donors, combined with progress in the control of the anti-porcine immune response and coagulation, has now enabled survival of up to 2 years. Although the pig-to-primate combination has long been considered a perfect reflection of the human situation, it has several limitations, particularly in terms of different natural anti-porcine antibodies. This fact, in association with survival prolongation, which is considered a prerequisite, has led some pioneering teams to cross the line of human application. However, use in humans will remain anecdotal, and further progress in renal xenotransplantation will be difficult to achieve without the use of non-human primates, which will remain complementary, particularly with regard to major innovations that have never been tested in humans.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"14003"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Transplantation and Donation After Circulatory Death in Children. A Review of the Technological, Logistical and Ethical Framework.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-14 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13801

Louise Amelia Kenny, Liz Armstrong, Marius Berman, Joe Brierley, David Crossland, John Dark, Dale Gardiner, Stephen Ralph Large, Derek Manas, Mohamed Nassar, David Shaw, Emma Simpson

{"title":"Heart Transplantation and Donation After Circulatory Death in Children. A Review of the Technological, Logistical and Ethical Framework.","authors":"Louise Amelia Kenny, Liz Armstrong, Marius Berman, Joe Brierley, David Crossland, John Dark, Dale Gardiner, Stephen Ralph Large, Derek Manas, Mohamed Nassar, David Shaw, Emma Simpson","doi":"10.3389/ti.2025.13801","DOIUrl":"https://doi.org/10.3389/ti.2025.13801","url":null,"abstract":"Heart transplant for adults following Donation after Circulatory Death (DCD) is well established in many parts of the world, including the United Kingdom (UK). Small child DCD hearts have now been recovered in the UK and internationally utilising novel technologies. Despite these recent advances, extension of this practice to pediatric cardiac transplantation has been slow and difficult despite the severe shortage of donors for children leading to a high number of deaths annually of children waiting for heart transplant. This is in direct contrast with the thriving UK programme of adult DCD heart transplant and pediatric DCD donation for non-cardiac organs. There has been insufficient action in addressing this inequality thus far. Barriers to development of a pediatric cardiac DCD programme are multifaceted: ethical concerns, technological paucity, financial and logistical hurdles. We describe the background, live issues, current developments and how we are driving resources toward a sustainable DCD programme for small children in the UK to provide valuable insights to other countries of the elements and principles at play. This is a call to responsible bodies to take urgent and achievable actions to establish an equitable paediatric DCD cardiac programme for donors, recipients and their families.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"13801"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytotoxic Responses Mediated by NK Cells and Cytotoxic T Lymphocytes in Xenotransplantation.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-12 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13867

Viktoriia Galdina, Gisella L Puga Yung, Jörg D Seebach

引用次数: 0

Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future. 单克隆抗体在肺移植受者中预防和早期治疗 COVID-19：单克隆抗体在肺移植受者COVID-19预防和早期治疗中的作用：系统综述及对单克隆抗体未来作用的展望》。

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-10 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13800

David A Van Eijndhoven, Robin Vos, Saskia Bos

{"title":"Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future.","authors":"David A Van Eijndhoven, Robin Vos, Saskia Bos","doi":"10.3389/ti.2025.13800","DOIUrl":"10.3389/ti.2025.13800","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes the clinical efficacy of mAbs against COVID-19 in adult LTR and provides a perspective on the role of mAbs for infectious diseases in the future. A systematic search of PubMed/MEDLINE, Embase and Cochrane was conducted for studies reporting clinical outcomes of adult LTR or solid organ transplant recipients (SOTR) including LTR with drug-specific outcomes. Twelve studies were included. Pre-exposure prophylaxis with mAbs reduced COVID-19 breakthrough infection in LTR. Early treatment of COVID-19 with mAbs correlated with a reduced incidence of severe COVID-19 outcomes, although statistical significance varied among studies. Overall, observational studies have demonstrated a potential benefit of mAbs in the treatment of COVID-19 in LTR, both in prophylaxis and early treatment, as well as the importance of early administration. Moreover, mAb therapy appeared safe and could be a viable option against other pathogens, a route that warrants further investigation.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382133, identifier CRD42022382133.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"13800"},"PeriodicalIF":2.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ethical Issues in Uncontrolled Donation After Circulatory Determination of Death: A Scoping Review to Reveal Areas of Broad Consensus, and Those for Future Research.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-06 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13992

Anastasia Georgiou, Weiyi Tan, Mihnea I Ionescu, Isla L Kuhn, Zoe Fritz

{"title":"Ethical Issues in Uncontrolled Donation After Circulatory Determination of Death: A Scoping Review to Reveal Areas of Broad Consensus, and Those for Future Research.","authors":"Anastasia Georgiou, Weiyi Tan, Mihnea I Ionescu, Isla L Kuhn, Zoe Fritz","doi":"10.3389/ti.2025.13992","DOIUrl":"10.3389/ti.2025.13992","url":null,"abstract":"Uncontrolled donation after circulatory determination of death (uDCD) protocols are established in several countries with good outcomes. We reviewed the literature between 1997 and 2024 to identify ethical issues. 33 papers were identified. Several areas of continued ethical debate were delineated: the role of advanced life support techniques; the ethical acceptability of aortic occlusion balloons; the nature and timing of consent to organ preserving techniques; whether best interests can/should extend beyond individual bodily integrity in this context. Further empirical research and ethical analyses are needed in these domains. Broad consensus was identified on several issues including: decisions about termination of resuscitation and entry into a uDCD protocol should be made by different teams; at least 20-30 min of cardio-pulmonary resuscitation is required; a hands-off period of 5-7 min is required alongside continuous monitoring; organ preserving techniques should be as minimally invasive as possible; families should be approached early to discuss organ donation by trained staff; public knowledge and engagement about uDCD is poor and must be improved; transparency and informed consent are essential for potential uDCD organ recipients. To maintain transparency and encourage positive public engagement we propose a name change from uDCD to Organ Donation after Sudden Irreversible Cardiac Arrest (ODASICA).","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"13992"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mono-HOPE Versus Dual-HOPE in Liver Transplantation: A Propensity Score-Matched Evaluation of Early Graft Outcome.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-05 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.13891

Dominik Thomas Koch, Micol Tamai, Malte Schirren, Moritz Drefs, Severin Jacobi, Christian M Lange, Matthias Ilmer, Hanno Nieß, Bernhard Renz, Jens Werner, Markus Guba, Dionysios Koliogiannis

{"title":"Mono-HOPE Versus Dual-HOPE in Liver Transplantation: A Propensity Score-Matched Evaluation of Early Graft Outcome.","authors":"Dominik Thomas Koch, Micol Tamai, Malte Schirren, Moritz Drefs, Severin Jacobi, Christian M Lange, Matthias Ilmer, Hanno Nieß, Bernhard Renz, Jens Werner, Markus Guba, Dionysios Koliogiannis","doi":"10.3389/ti.2025.13891","DOIUrl":"10.3389/ti.2025.13891","url":null,"abstract":"Hypothermic oxygenated machine perfusion (HOPE) has become an integral technique to enhance donor graft function in liver transplantation (LiTx). This study compares early posttransplant outcomes of mono-HOPE (portal vein perfusion only) versus dual- HOPE (both portal vein and hepatic artery perfusion). A retrospective analysis was conducted on 183 LiTx recipients, with 90 receiving mono-HOPE and 93 receiving dual-HOPE grafts. Propensity Score Matching (PSM) was applied, resulting in a matched cohort of 146 patients. Primary outcomes included one-year patient and graft survival, and non-anastomotic biliary strictures (NAS). Secondary outcomes included hospital length of stay (HLS). One-year patient survival was 81.7% in the mono-HOPE and 81.7% in the dual-HOPE group, and overall survival did not differ (p = 0.990). One-year death-censored graft survival was similarly comparable (91.2% vs. 93.3%, p = 0.893). NAS were observed in 10.96% in the mono-HOPE and 8.22% in the dual-HOPE group (p = 0.574). The median HLS was 29 days for both groups. Results suggest that dual-HOPE did not significantly improve patient or graft survival, nor did it reduce NAS or HLS compared to mono-HOPE. Assuming that larger cohorts and long-term follow-up data confirm this, additional cannulation of the hepatic artery during machine perfusion in hypothermic conditions may not be beneficial.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"13891"},"PeriodicalIF":2.7,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovations in Lung Transplant Research and Practice: The Future is Now.

IF 2.7 3区医学

Transplant International Pub Date : 2025-02-04 eCollection Date: 2025-01-01 DOI: 10.3389/ti.2025.14336

Robin Vos, Sandra Lindstedt, Deborah J Levine, Norihisa Shigemura

引用次数: 0